KRAS and non-small cell lung carcinoma: In current practice, all metastatic or locally advanced NSCLC should be tested for driver mutations including BRAF, MET, RET, NTRK, KRAS, HER2 if common mutations EGFR, ALK and ROS protooncogene are negative (55, 56).